Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402

Acta Oncologica

Volumn 51, Issue 6, 2012, Pages 768-773

  Nogami, Naoyuki ^a   Hotta, Katsuyuki ^b   Segawa, Yoshihiko ^a   Takigawa, Nagio ^b,g   Hosokawa, Shinobu ^c   Oze, Isao ^a   Fujii, Masanori ^a   Ichihara, Eiki ^b   Shibayama, Takuo ^d   Tada, Atsuhiko ^d   Hamada, Noboru ^d   Uno, Masatoshi ^e   Tamaoki, Akihiko ^c   Kuyama, Shoichi ^f   Ikeda, Genyo ^b   Osawa, Masahiro ^b   Takata, Saburo ^b   Tabata, Masahiro ^b   Tanimoto, Mitsune ^b   Kiura, Katsuyuki ^b  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c Okayama Red Cross Hospital   (Japan)

^d Department of Internal Medicine   (Japan)

^e Kaneda Hospital   (Japan)

^f CHUGOKU CENTRAL HOSPITAL   (Japan)

^g KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMRUBICIN; IRINOTECAN;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HUMAN; INFECTION; LEUKOPENIA; LIVER DISEASE; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE;

EID: 84863870899     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.648342     Document Type: Article

References (31)

1. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103. (Pubitemid 30324363)
2. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97. (Pubitemid 41079796)
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32. (Pubitemid 41058344)
4. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 2008;372:1809-18.
5. Bunn PA. Chemotherapy for advanced non-small-cell lung cancer: Who, what, when, why? J Clin Oncol 2002;20:23s-33s.
6. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722-6.
7. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, et al. Phase II study of irinotecan, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992;10:16-20.
8. Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N, et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 2003;88:335-41. (Pubitemid 36308141)
9. Ueoka H, Tanimoto M, Kiura K, Tabata M, Takigawa N, Segawa Y, et al. Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: A phase II study of Okayama Lung Cancer Study Group. Br J Cancer 2001;85:9-13. (Pubitemid 32695709)
10. Negoro S, Fukuoka M, Nakamura S, Ikegami H, Sugiura T, Ariyoshi Y, et al. Phase I - II study of amrubicin (SM-5887), a novel 9-amino-anthracycline, by iv administration for 3 consecutive days in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1995;14:abstr 1105.
11. Tan KB, Mattern MR, Eng WK, McCabe FL, Johnson RK. Nonproductive rearrangement of DNA topoisomerase I and II genes: Correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 1989;81:1732-5. (Pubitemid 19275912)
12. Sugimoto Y, Tsukahara S, Oh-hara T, Liu LF, Tsuruo T. Elevated expression of DNA topoisomerase II in camptothe cinresistant human tumor cell lines. Cancer Res 1990;50:7962-5.
13. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992;50:604-10.
14. Hotta K, Takigawa N, Kiura K, Tabata M, Umemura S, Ogino A, et al. Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer. Anti-cancer Res 2005;25:2429-34. (Pubitemid 41044726)
15. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997;111:1718-23. (Pubitemid 27260108)
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
17. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:3852-9. (Pubitemid 41079865)
18. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: A literature based meta-analysis of randomised trials. Ann Oncol 2004;15:1782-9. (Pubitemid 40012244)
19. Hotta K, Matsuo K. Long-standing debate on cisplatinversus carboplatin-based chemotherapy in the treatment of advanced non-small-cell lung cancer. J Thorac Oncol 2007;2:96. (Pubitemid 47163939)
20. Fukuda M, Ohe Y, Kanzawa F, Oka M, Hara K, Saijo N. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anticancer Res 1995;15:393-8.
21. Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, et al. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. Cancer Res 1989;49:4098-102. Shibayama (Pubitemid 19207242)
22. Shibayama T, Hotta K, Takigawa N, Tada A, Ueoka H, Harita S, et al. A phase I and pharmacological study of amrubicin and topotecan in patients of small cell lung cancer with relapsed or extensive-disease small cell lung cancer. Lung Cancer 2006;53:189-95.
23. Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008;26:5401-6.
24. Kato T, Nokihara H, Ohe Y, Yamamoto N, Sekine I, Kunitoh H, et al. Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 2006;24:abstr 7061.
25. Kaneda H, Kurata T, Tamura K, Uejima H, Nakagawa K, Fukuoka M. A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patients. Anticancer Res 2006;26:2479-85. (Pubitemid 43980221)
26. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009;27:2604-14.
27. Saito Y, Maekawa K, Ozawa S, Sawada J. Genetic polymorphisms and haplotypes of major drug metabolizing enzymes in East Asians and their comparison with other ethnic populations. Curr Pharmacogenomics 2007;5:49-78. (Pubitemid 46403580)
28. Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines: Greater cardiac safety versus conventional doxorubicin? Cancer 2004;100:2052-63. (Pubitemid 38580322)
29. Noda T, Watanabe T, Kohda A, Hosokawa S, Suzuki T. Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs 1998;16:121-8. (Pubitemid 28495213)
30. Yana T, Negoro S, Takada Y, Yokota S, Fukuoka M. Phase II study of amrubicin (SM-5887), a 9-amino-anthracycline, in previously untreated patients with extensive stage small-cell lung cancer (ES-SCLC): A West Japan Lung Cancer Group Trial. Proc Am Soc Clin Oncol 1998;17:450a(abstr 1734).
31. Ohe Y, Negoro S, Matsui K, Nakagawa K, Sugiura T, Takada Y, et al. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive stage small cell lung cancer (ED-SCLC). Proc Am Soc Clin Oncol 2004;23:664(abstr 7206).